Taivex Therapeutics Corporation   Report issue

For profit Phase 1
Founded: Taipei Taiwan (2009)

Organization Overview

First Clinical Trial
2017
NCT03195764
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Taivex Therapeutics Corporation

Active Ingredients

Drugs in Phase 1 Trials (3)

t-1101 (3 trials)

t-1201 (1 trial)

t-1301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 3